Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-800-23 botensilimab in advanced melanoma refractory to checkpoint inhibitors
2022-500652-37-00Phase 2Completed
- Sponsor
- Agenus Inc.
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of botensilimab in melanoma (2 cohorts), sponsored by Agenus Inc. Primary endpoint: Objective response rate. Started Oct 2022; status: completed.
02
Drugs
botensilimab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2022-500652-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500652-37-00.